Schering-Plough's Asmanex Clears FDA For Asthma
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of Asmanex will boost Schering's presence in the asthma therapy market, in which the company also markets Proventil HFA and Foradil. Schering's marketing for Asmanex is likely to focus on the product's dosing convenience.
You may also be interested in...
CFC-Containing Albuterol Inhalers To Be Removed By 2009
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.